Structure via PubChem · Public domain (PubChem)
(2R)-daptomycin
Sign in to saveAlso known as N-decanoyl-L-tryptophyl-L-asparaginyl-L-aspartyl-L-threonylglycyl-L-ornithyl-L-aspartyl-D-alanyl-L-aspartylglycyl-D-seryl-threo-3-methyl-L-glutamyl-3-anthraniloyl-L-alanine epsilon(1)-lactone, N-decanoyl-L-tryptophyl-L-asparaginyl-L-aspartyl-L-threonylglycyl-L-ornithyl-L-aspartyl-D-alanyl-L-aspartylglycyl-D-seryl-threo-3-methyl-L-glutamyl-3-anthraniloyl-L-alanine 1.13-3.4-lactone, LY 146032, daptomycin, CBC134
Daptomycin, sold under the brand name Cubicin among others, is a lipopeptide antibiotic used in the treatment of systemic and life-threatening infections caused by Gram-positive organisms.
Key facts
- Drug.ChEBI
- 600103
- Drug.ChEMBL
- 508162
- Drug.O
- 26
- Drug.Verifiedfields
- changed
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 457630808
- Drug.image
- Daptomycin Ball et al.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 300
- Drug.tradename
- Cubicin, Cubicin RF, Dapzura RT
- Drug.DailyMedID
- Daptomycin
- Drug.pregnancy_AU
- B1
- Drug.routes_of_administration
- Intravenous
- Drug.ATC_prefix
- J01
- Drug.ATC_suffix
- XX09
- Drug.legal_AU
- S4
- Drug.legal_UK
- POM
- Drug.legal_US
- Rx-only
via Wikipedia infobox
Chemical data
- Formula
- C72H101N17O26
- Molecular weight
- 1620.7 g/mol
- IUPAC name
- (3S)-4-[[(3S,6S,9R,15S,18R,21S,24S,30S,31R)-3-[2-(2-aminophenyl)-2-oxoethyl]-24-(3-aminopropyl)-15,21-bis(carboxymethyl)-6-[(2R)-1-carboxypropan-2-yl]-5,8,11,14,17,20,23,26,29-nonahydroxy-9-(hydroxymethyl)-18,31-dimethyl-2-oxo-1-oxa-4,7,10,13,16,19,22,25,28-nonazacyclohentriaconta-4,7,10,13,16,19,22,25,28-nonaen-30-yl]imino]-3-[[(2R)-1,4-dihydroxy-2-[[(2S)-1-hydroxy-2-(1-hydroxydecylideneamino)-3-(1H-indol-3-yl)propylidene]amino]-4-iminobutylidene]amino]-4-hydroxybutanoic acid
- SMILES
- CCCCCCCCCC(=N[C@@H](CC1=CNC2=CC=CC=C21)C(=N[C@H](CC(=N)O)C(=N[C@@H](CC(=O)O)C(=N[C@H]3[C@H](OC(=O)[C@@H](N=C([C@@H](N=C([C@H](N=C(CN=C([C@@H](N=C([C@H](N=C([C@@H](N=C([C@@H](N=C(CN=C3O)O)CCCN)O)CC(=O)O)O)C)O)CC(=O)O)O)O)CO)O)[C@H](C)CC(=O)O)O)CC(=O)C4=CC=CC=C4N)C)O)O)O)O
- InChIKey
- DOAKLVKFURWEDJ-QCMAZARJSA-N
- XLogP
- 0.7
- Polar surface area
- 748 Ų
- H-bond donors
- 23
- H-bond acceptors
- 42
- Formal charge
- 0
via PubChem
Research
3 papers- The Chiral Target of Daptomycin Is the 2R,2'S Stereoisomer of Phosphatidylglycerol.Angewandte Chemie (International ed. in English) · 2022
- A54145 Factor D Is Not Less Susceptible to Inhibition by Lung Surfactant than Daptomycin.ACS infectious diseases · 2022
- A Versatile Boc Solid Phase Synthesis of Daptomycin and Analogues Using Site Specific, On-Resin Ozonolysis to Install the Kynurenine Residue.Chemistry (Weinheim an der Bergstrasse, Germany) · 2019
via PubMed
Wikidata facts
- Mass
- 1619.710366
- Manufacturer
- Pfizer
- Has use
- medication
Show 12 more facts
- chemical formula
- C₇₂H₁₀₁N₁₇O₂₆
- Commons category
- Daptomycin
- defined daily dose
- 0.28
- canonical SMILES
- CCCCCCCCCC(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC3C(OC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC3=O)CCCN)CC(=O)O)C)CC(=O)O)CO)C(C)CC(=O)O)CC(=O)C4=CC=CC=C4N)C
- isomeric SMILES
- CCCCCCCCCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]3[C@@H](C)OC(=O)[C@H](CC(=O)C4=C(N)C=CC=C4)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCN)NC(=O)CNC3=O)[C@H](C)CC(O)=O
- medical condition treated
- bacterial infectious disease
- World Health Organisation international non-proprietary name
- daptomycin
- NCI Thesaurus ID
- C47470
- subject has role
- bactericide
- stylized name
- DAPTOmycin
- has characteristic
- biopharmaceutical
- significant drug interaction
- pravastatin
Sources (8)
via Wikidata · CC0
~16 min read
Encyclopedic overview
12 sectionsContents
- Medical uses
- Adverse effects
- Pharmacology
- Mechanism of action
- Microbiology
- Daptomycin resistance
- Efficacy
- Biosynthesis
- History
- References
- Further reading
- External links
Daptomycin, sold under the brand name Cubicin among others, is a lipopeptide antibiotic used in the treatment of systemic and life-threatening infections caused by Gram-positive organisms.
Daptomycin was removed from the World Health Organization's List of Essential Medicines in 2019. The World Health Organization classifies daptomycin as critically important for human medicine.
Excerpted from Wikipedia’s “(2R)-daptomycin” article, available under the CC BY-SA 4.0 licence.